Rezvan Ameli
Clinical Psychologist at the National Institutes of Health (NIH)
Data updated
Research Footprint
Rezvan Ameli appears in 5 tracked papers (2014–2023), most studied alongside Ketamine and Psilocybin, across Depressive Disorders, Major Depressive Disorder (MDD) and Anxiety Disorders.
Most-cited paper: Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety (283 citations).
Frequent co-authors: Carlos Zarate, David Luckenbaugh and Mark John Niciu.
Background & Research
Rezvan Ameli, PhD, is a clinical psychologist and mindfulness instructor at the NIH Clinical Center, where she has worked as a clinician, researcher, writer, and teacher for more than 20 years. Her earlier work focused on mindfulness, stress reduction, and psychological well-being, and she has held academic positions at Yale University, the University of Connecticut, and Howard University. More recently, she has coauthored studies on ketamine and psilocybin-assisted therapy in depression, bipolar depression, and cancer-related distress.
Key Impact
She has contributed to foundational NIH-HEALS and psychedelic-assisted therapy research in cancer patients, helping measure and characterize psycho-social-spiritual change and suicidal ideation outcomes in rapid-acting antidepressant studies.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Rezvan Ameli is associated with.
National Institutes of Health (NIH)
U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →Sunstone Therapies
A U.S. clinical research and care organization focused on psychedelic-assisted therapy delivery in structured clinical settings.
View stakeholder →